Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported final Phase 1 data for oral ITK inhibitor soquelitinib in moderate-to-severe atopic dermatitis at the 2026 SID meeting.
The 72‑patient randomized, placebo-controlled trial showed dose-dependent efficacy, durable drug‑free disease control and biomarker changes consistent with increased persistent Treg cells and reduced Th2/Th17 activity, according to Corvus.
At 200 mg twice daily, up to 75% of patients achieved EASI 75 and no severe or serious adverse events occurred, with adverse events comparable to placebo. Corvus is enrolling the ~200‑patient SIERRA1 Phase 2 trial, while Angel Pharmaceuticals runs a related Phase 1b/2 study in China.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported Q1 2026 results and a business update on May 7, 2026. Key clinical advances include positive Phase 1 cohort 4 data for soquelitinib, Phase 2 initiation in atopic dermatitis, ongoing Phase 3 PTCL enrollment, and planned Phase 2 trials in hidradenitis suppurativa and asthma. Cash and marketable securities were $236.7M at March 31, 2026, expected to fund operations into Q2 2028.
Corvus Pharmaceuticals (Nasdaq: CRVS) appointed Andrew C. Chan, M.D., Ph.D., to its Board of Directors effective April 23, 2026. Dr. Chan brings 25 years of research leadership at Genentech, including Senior VP, Research Biology (2010–2025), and deep expertise in immunology and T cell signaling.
The addition is presented as strengthening scientific oversight as Corvus advances soquelitinib and its ITK inhibition platform across immune, inflammatory diseases, and cancer.
Corvus Pharmaceuticals (Nasdaq: CRVS) will host an in-person and virtual investor and analyst meeting on May 14, 2026 to highlight final Phase 1 soquelitinib data presented at the Society for Investigative Dermatology (SID) Annual Meeting.
Two oral presentations (one late-breaker) will detail immunologic and biomarker results and reports of prolonged drug-free remissions. The company will report Q1 2026 financial results on May 7, 2026; no conference call will accompany that release this quarter.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported Q4 and full‑year 2025 results and a business update on March 12, 2026. Key items: positive Phase 1 cohort 4 atopic dermatitis data (EASI75 75% for soquelitinib vs 20% placebo), initiation of a Phase 2 atopic dermatitis trial, ongoing Phase 3 PTCL registrational trial, and a completed public offering with ~$189M net proceeds that extends cash runway into Q2 2028.
R&D spend rose notably in 2025; conference call and webcast held March 12, 2026 at 4:30 p.m. ET.
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The event offers live dial-in, instant telephone access, and a webcast via investor relations. A replay will be available on Corvus' website for 90 days.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present a corporate overview and hold one-on-one investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40pm ET.
According to the company, the event is virtual and a webcast will be available live and for 90 days via the investor relations section of Corvus' website.
Corvus Pharmaceuticals (Nasdaq: CRVS) closed an upsized underwritten public offering of 9,085,778 common shares, including full exercise of the underwriters’ option for 1,185,101 additional shares, at $22.15 per share. Gross proceeds are expected to be approximately $201.2 million before underwriting discounts and offering expenses. The company intends to use net proceeds for working capital and general corporate purposes, including Phase 3 T‑cell lymphoma and Phase 2 trials in atopic dermatitis, hidradenitis suppurativa and asthma.
Corvus Pharmaceuticals (Nasdaq: CRVS) priced an upsized underwritten public offering of 7,900,677 shares at $22.15 per share, expected to generate approximately $175.0 million in gross proceeds before fees. The company granted underwriters a 30-day option to purchase up to an additional 1,185,101 shares at the public offering price less discounts.
Corvus said it expects to use net proceeds for working capital and general corporate purposes, including funding its Phase 3 T‑cell lymphoma trial and Phase 2 trials in atopic dermatitis, hidradenitis suppurativa and asthma. The offering is expected to close on or about January 23, 2026.
Corvus Pharmaceuticals (Nasdaq: CRVS) commenced an underwritten public offering of $150,000,000 of common stock and pre-funded warrants on January 20, 2026, with a 30-day underwriter option to purchase up to an additional $22,500,000 of common stock. Net proceeds are expected to be used for working capital and general corporate purposes, including capital expenditures and research and development for its Phase 3 T cell lymphoma program and Phase 2 trials in atopic dermatitis, hidradenitis suppurativa and asthma. Jefferies and Goldman Sachs are lead managers. The offering is subject to market conditions and will be made by prospectus supplement under an S-3 shelf declared effective August 15, 2024.